Exkivity Prices, Coupons and Patient Assistance Programs
Exkivity (mobocertinib) is a member of the EGFR inhibitors drug class and is commonly used for Non-Small Cell Lung Cancer.
The cost for Exkivity oral capsule 40 mg is around $28,177 for a supply of 120 capsules, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Exkivity is available as a brand name drug only, a generic version is not yet available. View generic Exkivity availability for more details.
Exkivity prices
Oral Capsule
Quantity | Per unit | Price |
---|---|---|
120 | $234.81 | $28,177.25 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, CVS Pharmacy, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Exkivity Coupons, Copay Cards and Rebates
Exkivity offers may be in the form of a printable coupon, rebate, savings or copay card, trial offer, or free samples. Some offers may be printed right from a website, others require registration, completing a questionnaire, or obtaining a sample from the doctor's office.
Exkivity Takeda Oncology Co-Pay Assistance Program: Eligible commercially insured patients may pay as little as $0 per prescription per year; co-pay card can be renewed every 12 months subject to continued eligibility; for additional information contact the program at 844-817-6468 option 2.
- Applies to:
- Exkivity
- Number of uses:
- per prescription per year
Form more information phone: 844-817-6468 or Visit website
Exkivity Takeda Oncology Co-Pay Assistance Program Rebate: Eligible commercially insured patients may be eligible to receive a rebate if they were unable to take advantage of the savings at their pharmacy while already enrolled in the program; patient must have paid in full for their prescription to be eligible; for additional information contact the program at 844-817-6468 option 2.
- Applies to:
- Exkivity
- Number of uses:
- One rebate per prescription fill
Form more information phone: 844-817-6468 or Visit website
Patient Assistance & Copay Programs for Exkivity
Patient assistance programs (PAPs) are usually sponsored by pharmaceutical companies and provide free or discounted medicines and copay programs to low income or uninsured and under-insured people who meet specific guidelines. Eligibility requirements vary for each program.
Provider: Patient Access Network Foundation (PAN)
Elligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Exkivity (mobocertinib) Capsule
More information please phone: 866-316-7263 Visit Website
Provider: Takeda Oncology Here2Assist
Elligibility requirements:- Contact program for details.
- Not disclosed
- Medically appropriate condition/diagnosis
- Must be residing in the US or Puerto Rico
- Co-payment assistance, and patient assistance programs are available for eligible patients.
- Exkivity (mobocertinib) Capsule
More information please phone: 844-817-6468 Visit Website
More about Exkivity (mobocertinib)
- Check interactions
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: EGFR inhibitors
- En español